Zafirlukast for Ovarian Cancer

Overseen by Rushad Patell, MD

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Beth Israel Deaconess Medical Center

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing Zafirlukast, an asthma medication, to see if it can help patients with relapsed ovarian cancer. The drug may reduce tumor activity and lower the risk of blood clots based on lab studies. Zafirlukast is commonly used to improve asthma control.

Research Team

Rushad Patell, MD

Principal Investigator

Beth Israel Deaconess Medical Center

Eligibility Criteria

This trial is for adult women with a specific type of ovarian cancer that has relapsed, indicated only by tumor markers without visible disease. They must have finished initial chemotherapy and surgery successfully, be able to swallow pills, and use contraception if childbearing potential. Men and those with certain health conditions or on conflicting medications are excluded.

Inclusion Criteria

I am 18 years old or older.

My CA-125 levels have doubled without signs of cancer on scans.

I've completed initial chemotherapy and surgery for my cancer without it getting worse.

Exclusion Criteria

I have side effects from cancer treatment, but they are mild except for hair loss or nerve issues.

I am not pregnant or breastfeeding.

I am currently on blood thinner medication.

Treatment Details

Interventions

• Zafirlukast (Leukotriene Inhibitor)

Trial Overview The study tests Zafirlukast's effectiveness in preventing tumor activity in women whose ovarian cancer has returned but is only detectable through tumor markers rather than physical tumors. Participants will take Zafirlukast tablets to see if it can control the cancer's return.

Participant Groups

Group I: Zafirlukast Experimental Treatment 1 Intervention

Zafirlukast will be taken orally at a pre-determined dose 2x daily for 28 day cycle up to 1 year.

Who Is Running the Clinical Trial?

Beth Israel Deaconess Medical Center

Lead Sponsor

Trials

872

Recruited

12,930,000+

Dr. Kevin Tabb

Beth Israel Deaconess Medical Center

Chief Executive Officer since 2021

MD from Hebrew University Hadassah Medical School

Dr. Chi Chang Daniel Siao

Beth Israel Deaconess Medical Center

Chief Medical Officer since 2023

MD from King George’s Medical University

Dana-Farber Cancer Institute

Collaborator

Trials

1,128

Recruited

382,000+

Dr. Benjamin L. Ebert

Dana-Farber Cancer Institute

Chief Executive Officer

MD from Harvard Medical School, PhD from Oxford University

Dr. Craig A. Bunnell

Dana-Farber Cancer Institute

Chief Medical Officer since 2012

MD from Harvard Medical School, MPH from Harvard School of Public Health, MBA from MIT Sloan School of Management

National Institutes of Health (NIH)

Collaborator

Trials

2,896

Recruited

8,053,000+

Dr. Jeanne Marrazzo

National Institutes of Health (NIH)

Chief Medical Officer

MD from University of California, Los Angeles

Dr. Jay Bhattacharya

National Institutes of Health (NIH)

Chief Executive Officer

MD, PhD from Stanford University

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School